Bruker Corporation is a Billerica, Massachusetts-based developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable scientists and engineers to explore life and materials at molecular, cellular, and microscopic levels, with the Company positioning itself as a leader of the post-genomic era across the Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST) segments. For the second quarter ended June 30, 2026, the Company generated revenue of $838.5 million, up 5.2 percent year-over-year, with organic revenue growth of 2.8 percent (3.4 percent excluding tariff refunds), constant-exchange-rate growth of 4.3 percent, and a favorable foreign currency impact of 0.9 percent. The BSI segment revenue of $767.3 million increased 4.7 percent year-over-year with 2.3 percent organic growth, and the BSI bookings grew 10 percent organically with a book-to-bill ratio exceeding 1.0x. The BEST segment revenue of $74.2 million increased 11.9 percent year-over-year with 8.9 percent organic growth net of intercompany eliminations. The GAAP operating loss of $(65.3) million reflects a $134.9 million non-cash goodwill impairment charge, while the non-GAAP operating income of $118.5 million (14.1 percent margin) was up 64.6 percent from $72.0 million (9.0 percent margin) in the prior-year quarter. Non-GAAP diluted EPS of $0.49 was up 53.1 percent from $0.32. The Company updated FY2026 guidance to $3.54-3.57 billion in revenue (3-4 percent growth, 1-2 percent organic) and non-GAAP EPS of $2.10-2.15 (15-17 percent growth), with the guidance update reflecting only currency and tax adjustments.
The investment thesis rests on three variables. The BSI bookings inflection is the load-bearing demand variable, with Q2 2026 BSI organic bookings up 10 percent year-over-year and a book-to-bill above 1.0x signaling that the order pipeline is rebuilding after a period of academic and government demand softness, and the strategic intent is to convert the bookings strength into sustained organic revenue growth. The non-GAAP margin expansion trajectory is the load-bearing profitability variable, with Q2 2026 non-GAAP operating margin of 14.1 percent up 510 basis points from 9.0 percent in Q2 2025, driven by cost discipline, pricing, and operating leverage on the returning volume, and the strategic intent is to continue expanding margins through the gradual market recovery into 2027. The BEST segment acceleration is the load-bearing growth variable, with Q2 2026 BEST organic revenue up 8.9 percent year-over-year (net of intercompany eliminations) driven by energy research and superconducting applications, and the strategic intent is to continue building the BEST franchise as a higher-growth, higher-margin complement to the core BSI business.